Compare · RVMD vs VCKA
RVMD vs VCKA
Side-by-side comparison of Revolution Medicines Inc. (RVMD) and Vickers Vantage Corp. I (VCKA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both RVMD and VCKA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- RVMD is the larger of the two at $39.87B, about 228.9x VCKA ($174.1M).
- RVMD has hit the wire 2 times in the past 4 weeks while VCKA has been quiet.
- RVMD has more recent analyst coverage (25 ratings vs 0 for VCKA).
- Company
- Revolution Medicines Inc.
- Vickers Vantage Corp. I
- Price
- $187.59-2.32%
- $8.51-15.74%
- Market cap
- $39.87B
- $174.1M
- 1M return
- +0.13%
- -
- 1Y return
- +404.82%
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2021
- News (4w)
- 2
- 0
- Recent ratings
- 25
- 0
Revolution Medicines Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.
Vickers Vantage Corp. I
Vickers Vantage Corp. I does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2020 and is based in Singapore.
Latest RVMD
- Revolution Medicines to Report Financial Results for Second Quarter 2026 After Market Close on August 5, 2026
- Revolution Medicines’ New Drug Application for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic Pancreatic Cancer
- European Medicines Agency Expedites Assessment of Revolution Medicines’ Daraxonrasib Under Phased Review Process
- Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
- Director Patel Sushil exercised 2,955 shares at a strike of $37.54 and sold $1,048,967 worth of shares (5,580 units at $187.99) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 21,656 units (SEC Form 4)
- Chief Financial Officer Anders Jack exercised 20,000 shares at a strike of $18.56 and sold $3,366,604 worth of shares (20,000 units at $168.33) as part of a pre-agreed trading plan (SEC Form 4)
- Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
- Director Kim Lorence H. was granted 1,191 shares, increasing direct ownership by 2% to 74,281 units (SEC Form 4)
- Director Borisy Alexis was granted 1,191 shares, increasing direct ownership by 0.05% to 2,340,075 units (SEC Form 4)
- Director Anderson Elizabeth M was granted 1,191 shares, increasing direct ownership by 14% to 9,406 units (SEC Form 4)
Latest VCKA
- SEC Form 8-K filed by Vickers Vantage Corp. I
- SEC Form SC 13D/A filed by Vickers Vantage Corp. I (Amendment)
- SEC Form EFFECT filed by Vickers Vantage Corp. I
- SEC Form 424B5 filed by Vickers Vantage Corp. I
- SEC Form S-3/A filed by Vickers Vantage Corp. I (Amendment)
- Vickers Vantage Corp. I filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 424B3 filed by Vickers Vantage Corp. I
- SEC Form 424B3 filed by Vickers Vantage Corp. I
- SEC Form 424B3 filed by Vickers Vantage Corp. I
- SEC Form 424B3 filed by Vickers Vantage Corp. I